Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): R327

            Therapeutic Area: Infections and Infectious Diseases Product Name: R327

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 01, 2021

            Details:

            RECCE® 111 is a non-descript title for an experimental compound, developed in-house, building upon the unique mechanisms of action of RECCE® 327. Positive sinusitis infection data indicated in animal study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PBT2

            Therapeutic Area: Infections and Infectious Diseases Product Name: PBT2

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Alterity Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership December 21, 2020

            Details:

            The licensed technology combines Alterity’s PBT2 and other zinc ionophores with commonly used antibiotics to treat infections caused by multidrug resistant bacteria. This is an opportunity for Alterity to further leverage its investment in PBT2.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IMM-124E

            Therapeutic Area: Infections and Infectious Diseases Product Name: Travelan

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Monash University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 15, 2020

            Details:

            A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance/s in Immuron’s marketed products (IMM-124E).